State of New Jersey Common Pension Fund D Sells 8,643 Shares of Twist Bioscience Co. (NASDAQ:TWST)

State of New Jersey Common Pension Fund D lowered its position in Twist Bioscience Co. (NASDAQ:TWSTGet Rating) by 14.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 52,771 shares of the company’s stock after selling 8,643 shares during the period. State of New Jersey Common Pension Fund D owned about 0.09% of Twist Bioscience worth $1,860,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. US Bancorp DE boosted its holdings in Twist Bioscience by 289.8% in the 3rd quarter. US Bancorp DE now owns 6,568 shares of the company’s stock worth $232,000 after buying an additional 4,883 shares during the period. Slow Capital Inc. boosted its holdings in shares of Twist Bioscience by 4.7% during the 3rd quarter. Slow Capital Inc. now owns 67,280 shares of the company’s stock valued at $2,371,000 after purchasing an additional 3,035 shares during the last quarter. Baillie Gifford & Co. bought a new position in shares of Twist Bioscience during the 3rd quarter valued at about $31,398,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of Twist Bioscience by 12.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,023 shares of the company’s stock valued at $106,000 after purchasing an additional 333 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Twist Bioscience by 5.3% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,819,896 shares of the company’s stock valued at $99,373,000 after purchasing an additional 142,726 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms have commented on TWST. Scotiabank began coverage on shares of Twist Bioscience in a report on Wednesday, January 4th. They set a “sector outperform” rating and a $33.00 price objective for the company. Barclays dropped their price objective on shares of Twist Bioscience from $45.00 to $43.00 and set an “overweight” rating for the company in a report on Monday, November 21st. Robert W. Baird decreased their target price on shares of Twist Bioscience from $56.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, November 21st. Evercore ISI upgraded shares of Twist Bioscience from an “in-line” rating to an “outperform” rating and upped their target price for the company from $28.00 to $36.00 in a research report on Tuesday, January 3rd. Finally, SVB Leerink decreased their target price on shares of Twist Bioscience from $45.00 to $30.00 and set a “market perform” rating on the stock in a research report on Monday, November 21st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $38.33.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $27.03 on Friday. Twist Bioscience Co. has a 1-year low of $21.78 and a 1-year high of $66.15. The firm has a market capitalization of $1.53 billion, a P/E ratio of -6.71 and a beta of 1.11. The company’s 50-day moving average is $25.71 and its 200 day moving average is $34.59.

Twist Bioscience (NASDAQ:TWSTGet Rating) last posted its quarterly earnings data on Friday, November 18th. The company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.37. The company had revenue of $57.31 million for the quarter, compared to analyst estimates of $56.99 million. Twist Bioscience had a negative net margin of 107.02% and a negative return on equity of 28.89%. Research analysts anticipate that Twist Bioscience Co. will post -4.53 earnings per share for the current fiscal year.

Twist Bioscience Profile

(Get Rating)

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Further Reading

Institutional Ownership by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.